China Rush Over? Korean Firms Step Up To Seize Opportunities
Strong BIO Presence Signals Intent
Executive Summary
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
You may also be interested in...
Hard Decoupling: Foreign Firms Less Optimistic About China But Health Sector Revenues Growing
Latest US trade group business survey shows R&D-based pharma and medical device companies continue to see China as an important growth driver but amid unequal market access, ongoing regulatory concerns, and patchy IP protection improvements.
Lunsumio Provides First Test For Korea's Breakthrough Therapy Program
South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.